Poster Presentations

THURSDAY, 14 JUNE 2018

Genomics, genetic basis of disease and antigen presentation

THU0001 DIFFERENTIAL METHYLATION AS A PREDICTOR OF METHOTREXATE RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS

N. Nair¹, D. Plant^{1,2}, S.M. Verstappen³, J.D. Isaacs⁴, A.W. Morgan⁵, K.L. Hyrich³, A. Barton¹, A.G. Wilson⁶, on behalf of MATURA. ¹Arthritis Research UK Centre for Genetics and Genomics, University of Manchester; ²NIHR Manchester Musculoskeletal BRC, CMFT; ³Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester; ⁴NIHR Newcastle BRC, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle; ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; ⁶University College Dublin School of Medicine and Medical Science, University College Dublin, Dublin, Ireland

Background: Methotrexate (MTX) is recommended as the first-line disease modifying anti-rheumatic drug (csDMARD) for the treatment of rheumatoid arthritis (RA), but up to 40% patients do not respond adequately, or experience adverse effects¹; therefore, identifying blood-based biomarkers that predict treatment response is a research priority. DNA methylation is an epigenetic marker that modifies but does not alter DNA sequence; MTX may act, at least in part, by inhibiting intracellular methyl donor transfer leading to DNA hypomethylation² so DNA methylation may act as a biomarker of MTX response.

Objectives: To identify differential DNA methylation signatures in whole blood associated with response to MTX in patients with RA.

Methods: DNA methylation was measured using the HumanMethylation450 BeadChip in DNA samples from individuals recruited to the Rheumatoid Arthritis Medication Study (RAMS). Demographic and clinical data were collected prior to starting MTX (baseline) and at 6 months after commencing MTX. DNA was extracted from whole blood samples collected at baseline and at 4 weeks from patients who, at 6 months, had a EULAR good response (n=36) or EULAR poor response (n=36) to MTX. Differentially methylated positions (DMPs) between baseline and 4 weeks, and between good and poor response groups were identified using a linear model, adjusting for gender, age, cell composition, baseline disease activity score (DAS28), and smoking status. Additional analyses were performed to assess the association between methylation and change in DAS28 score and the individual DAS28 components over 6 months. DMPs with significant differences were selected for replication by pyrosequencing in an independent group of 100 patients with both baseline and 4 week samples available for testing. Using genome-wide genotype data for the same patients, replicated DMPs were investigated for methylation QTLs (meQTLs).

Results: The initial analysis identified differential methylation between good and poor responders at 2 CpG sites (DMPs) in samples taken at 4 weeks, with response status determined at 6 months (p-value<10⁻⁵). Three other DMPs were associated with change in tender joint count, another 3 DMPs with change in swollen joint count, and a further 4 DMPs were associated with change in C-reactive protein (CRP). Of the 12 DMPs, 4 showed replicated association with improvement of swollen joint count and lower CRP levels at 6 months in the pyrosequencing dataset (p-value<0.01). However, there were no meQTLs identified at these loci.

Conclusions: These results suggest DNA methylation may provide a biomarker of MTX response but requires replication in other larger data sets.

REFERENCES:

- [1] Verstappen SMM, et al. *Int. J. Clin. Rheu* 2012;7(5):559–567.
- [2] Kim Y, et al. *J. Lab. Clin. Med* 1996;128:165–172.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.4680

THU0002 NOVEL PATHOGENIC STOP CODON MUTATION IN THE NF-KB P65 SUBUNIT (RELA) ASSOCIATED WITH BOTH BEHÇET'S DISEASE LIKE SYNDROME AND NEUROMYELITIS OPTICA IN AN IRISH FAMILY

F. Adeeb^{1,2}, E.R. Dorris³, S. Tariq², W.L. Ng², A.G. Stack¹, A.G. Wilson³, A. D. Fraser². ¹Graduate Entry Medical School, University of Limerick; ²Department of Rheumatology, University Hospital Limerick, Limerick; ³EULAR Centre of Excellence/UCDCentre for Arthritis Research, Conway Institute of Biomolecular and Biomedical Research, Dublin, Ireland

Background: Behçet's disease (BD) has a complex multifactorial pathogenesis and presents with phenotypic heterogeneity predominantly mucocutaneous ulcerations, ocular lesions and skin manifestations. More recently, there have been reported cases of monogenic spectrum defects presented with BD-like similarities or phenotype.

Objectives: We investigated an Irish Caucasian family of eleven that included two half-sisters with early-onset BD, and another sister with neuromyelitis optica, all who were born to asymptomatic non-consanguineous parents. More recently, one of the sisters' daughter developed recurrent oral aphthosis at the age of 10 years old.

Methods: Peripheral blood mononuclear cells were extracted from patients and non-affected donor blood using standard fractionation methods. Following quality assessment and quantification whole exome sequencing was performed on all participants.

Results: Whole exome sequencing data identified segregation of a novel pathogenic stop codon mutation in the nuclear factor NF-κB p65 subunit (RelA) resulting in a non-functional protein. The mutation involves cytosine deletion and results in a His487ThrfsTer7 frameshift (His487ThrfsTer7) RelA resulting in loss of transcription activation-1 (TA1) and a portion of TA2 from RelA. The mutation was seen within the three generations, including the three half-sisters, their father as well as one of the proband's daughter, potentially describing a new syndrome.

Conclusions: Our study suggests that loss-of-function mutations in the NF-κB pathway, a pivotal mediator of inflammation and apoptosis, are linked with the development of familial early-onset BD-like syndromes. Better insights and further understanding of this "orphan" immunogenetic syndrome carries high clinical impact to assist early disease recognition and potential discoveries of novel targeted therapies.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.3889

THU0003 COMPREHENSIVE EVALUATION OF THE EFFECTS OF RARE AND COMMON EXONIC ABCG2 VARIANTS ON GOUT SUSCEPTIBILITY

T. Higashino¹, T. Takada², H. Nakaoka³, Y. Toyoda², B. Stiburkova⁴, K. Wakai⁵, H. Ooyama⁶, I. Inoue³, T.R. Merriman⁷, N. Shinomiya¹, H. Matsuo¹. ¹Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Tokorozawa; ²Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo, Tokyo; ³Division of Human Genetics, Department of Integrated Genetics, National Institute of Genetics, Mishima, Japan; ⁴Institute of Rheumatology, Prague, Czech Republic; ⁵Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya; ⁶Ryugoku East Gate Clinic, Tokyo, Japan; ⁷Department of Biochemistry, University of Otago, Dunedin, New Zealand

Background: Gout is the most common form of inflammatory arthritis and is caused by hyperuricemia. Many previous studies have indicated that common dysfunctional variants of the gene encoding ATP-binding cassette transporter subfamily G member 2/breast cancer resistance protein (ABCG2/BCRP) increase the risk of gout and hyperuricemia. In addition, we recently showed that rare non-synonymous variants are also risk factors for gout. However, we have not evaluated the effects of synonymous and splice-site variants of